CO7240391A2 - Proceso de aislamiento/purificación de células tumorales y métodos de uso del mismo - Google Patents

Proceso de aislamiento/purificación de células tumorales y métodos de uso del mismo

Info

Publication number
CO7240391A2
CO7240391A2 CO14273304A CO14273304A CO7240391A2 CO 7240391 A2 CO7240391 A2 CO 7240391A2 CO 14273304 A CO14273304 A CO 14273304A CO 14273304 A CO14273304 A CO 14273304A CO 7240391 A2 CO7240391 A2 CO 7240391A2
Authority
CO
Colombia
Prior art keywords
methods
tumor cells
assays
isolation
purification process
Prior art date
Application number
CO14273304A
Other languages
English (en)
Inventor
Cary Presant
Mathieu Perree
Allan E Hallquist
Original Assignee
Diatech Oncology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatech Oncology filed Critical Diatech Oncology
Publication of CO7240391A2 publication Critical patent/CO7240391A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan en la presente métodos para aislar y purificar células tumorales hematológicas o no hematológicas útiles en una variedad de ensayos y procedimientos, incluyendo la detección de la eficacia del fármaco para tumores, tales como ensayos cinéticos de microcultivos. También se divulgan ensayos cinéticos de microcultivos y métodos adecuados para comparar la eficacia relativa de fármacos anticancerosos genéricos versus fármacos anticancerosos de marca.
CO14273304A 2012-05-15 2014-12-12 Proceso de aislamiento/purificación de células tumorales y métodos de uso del mismo CO7240391A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261647248P 2012-05-15 2012-05-15

Publications (1)

Publication Number Publication Date
CO7240391A2 true CO7240391A2 (es) 2015-04-17

Family

ID=49584132

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14273304A CO7240391A2 (es) 2012-05-15 2014-12-12 Proceso de aislamiento/purificación de células tumorales y métodos de uso del mismo

Country Status (17)

Country Link
US (2) US20150160193A1 (es)
EP (1) EP2850434A4 (es)
JP (1) JP2015517662A (es)
KR (1) KR20150035537A (es)
CN (1) CN104704368A (es)
AU (1) AU2013263337A1 (es)
BR (1) BR112014028396A2 (es)
CA (1) CA2873180A1 (es)
CO (1) CO7240391A2 (es)
CR (1) CR20140575A (es)
HK (1) HK1208727A1 (es)
IL (1) IL235709A0 (es)
IN (1) IN2014DN09582A (es)
MX (1) MX2014013939A (es)
SG (1) SG11201407497TA (es)
TW (1) TW201409029A (es)
WO (1) WO2013172955A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9476871B2 (en) 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
AU2014215675B2 (en) * 2013-02-06 2018-08-30 Intervet International B.V. System and method for determining antibiotic effectiveness in respiratory diseased using auscultation analysis
EP3083686B2 (en) * 2013-12-17 2023-03-22 F. Hoffmann-La Roche AG Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
SG10202007520WA (en) 2016-03-02 2020-09-29 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
TWI662130B (zh) * 2018-09-21 2019-06-11 國立臺灣大學 分離循環癌細胞之方法
CN111019897B (zh) * 2019-02-14 2023-08-11 中山大学孙逸仙纪念医院 人良性叶状肿瘤细胞系glk-1010及其应用
CN111019898B (zh) * 2019-02-14 2023-07-21 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系hjp-0320及其应用
CN111019899B (zh) * 2019-02-14 2023-08-04 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系lj-0429及其应用
CN113466417B (zh) * 2021-05-13 2023-03-21 柳州东风容泰化工股份有限公司 一种氟尿嘧啶的制备纯度评估方法及系统
WO2024054627A1 (en) * 2022-09-08 2024-03-14 The University Of North Carolina At Chapel Hill Diagnosis of patient tumor tissue

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2438497A (en) * 1996-04-05 1997-10-29 Johns Hopkins University, The A method of enriching rare cells
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
AU2002239491A1 (en) * 2000-11-09 2002-05-27 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
KR100721927B1 (ko) * 2006-10-31 2007-05-28 이수앱지스 주식회사 암조직에서 암세포를 분리하는 방법
IT1391619B1 (it) * 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
US20110244503A1 (en) * 2010-03-31 2011-10-06 Perree Mathieu System and Method for Anti-Cancer Drug Candidate Evaluation
BR112012024619A2 (pt) * 2010-03-31 2016-05-31 Diatech Oncology Llc sistema e método para avaliação de candidato a medicamento anticancer
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Also Published As

Publication number Publication date
EP2850434A4 (en) 2016-01-13
EP2850434A1 (en) 2015-03-25
WO2013172955A9 (en) 2014-02-27
US20150160193A1 (en) 2015-06-11
KR20150035537A (ko) 2015-04-06
TW201409029A (zh) 2014-03-01
AU2013263337A1 (en) 2014-12-04
US20170336391A1 (en) 2017-11-23
BR112014028396A2 (pt) 2018-05-29
CN104704368A (zh) 2015-06-10
CR20140575A (es) 2015-05-07
IN2014DN09582A (es) 2015-07-17
JP2015517662A (ja) 2015-06-22
SG11201407497TA (en) 2014-12-30
IL235709A0 (en) 2015-01-29
CA2873180A1 (en) 2013-11-21
MX2014013939A (es) 2015-05-11
WO2013172955A1 (en) 2013-11-21
HK1208727A1 (en) 2016-03-11

Similar Documents

Publication Publication Date Title
CO7240391A2 (es) Proceso de aislamiento/purificación de células tumorales y métodos de uso del mismo
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
GB201106743D0 (en) Novel compounds
EP2922818A4 (en) HYDROPHILIC LINKS AND THEIR USES FOR CONJUGATION OF MEDICAMENTS TO CELL-BINDING MOLECULES
WO2013150495A3 (en) Preparation of ticagrelor
BR112014024494A2 (pt) dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
MX350539B (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
BR112015031027A2 (pt) Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
ECSP13013060A (es) Composiciones de nucleasa terapéuticas y métodos
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
MX363270B (es) Composiciones y metodos para inhibir la polimerasa viral.
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
CL2015001020A1 (es) Compuestos derivados de 4-carboxamido-isoindolinona, inhibidores selectivos de parp-1; proceso de preparacion; composicion farmaceutica; un metodo in vitro; un producto; y su uso como medicamento con actividad antineoplasica
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12014502834A1 (en) Pharmaceutical form for extended release of active substances
WO2013188750A3 (en) Substituted macrocyclic compounds having proteasome inhibitory activity